Bodyport

Bodyport is a San Francisco-based digital therapeutics and health technology company founded in 2014.

The company focuses on developing noninvasive, biomarker-guided devices aimed at managing complex chronic conditions, particularly heart disease. Bodyport's mission is to empower individuals with actionable health information through everyday tools used at home, specifically targeting heart failure, which affects millions of Americans. The company's flagship product is the Bodyport Cardiac Scale, a standard weighing scale equipped with advanced cardiovascular sensors. This device allows for real-time monitoring of heart function and fluid status without the need for wearables or surgical implants. Data collected is transmitted to healthcare providers, enabling timely interventions and remote patient management. Bodyport's technology is designed to be FDA-cleared, ensuring safety and compliance for clinical use. With a workforce of around 14 employees, Bodyport has raised approximately $15.8 million in funding from notable investors, including Y Combinator and Boehringer Ingelheim Venture Fund. The company aims to expand its platform to address additional chronic conditions in the future.